VIDEO: OlympiA finding 'speaks to the importance' of family history, genetic testing
Click Here to Manage Email Alerts
In this video, Daphna Yael Spiegel, MD, an instructor in radiation oncology at Beth Israel Deaconess Medical Center, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.
In this randomized and double-blind phase 3 study, researchers evaluated the efficacy of the PARP inhibitor olaparib in patients with BRCA1/2 germline mutations who had HER2-negative high-risk early breast cancer who previously received primary local treatment and adjuvant chemotherapy or neoadjuvant chemotherapy.
Researchers found that receiving the olaparib following treatment with ACT or NACT significantly improved invasive disease-free survival and distant disease-free survival and had acceptable toxicity in patients with germline BRCA1/2 mutations and HER2-negative high-risk early breast cancer.
“Although there was no overall survival benefit that was statistically significant yet, these are early results triggered by an interim analysis, and there may be more to come in the future,” Spiegel said.
She added that the study “speaks to the importance of good family history and sending appropriate patients for genetic testing, because we can now give tailored treatments to patients with these underlying genetic mutations that notoriously have high rates of recurrence,” Spiegel said.
Collapse
Click Here to Manage Email Alerts